[PL]Promoting the Advancement of the Pharmaceutical Society of Japan
○Shigeki Sasaki1(1. Pharm. Sci., Nagasaki Int. Univ.)
The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)
Mar 26 - Mar 29, 2021Virtual Meeting
You can search for presentations in this event.
Search
The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)
Mar 26 - Mar 29, 2021Virtual Meeting
You can search for presentations in this event.
SearchSearch Results(2,821)
[SP]Message to pharmacy students, educators, researchers and pharmacists from an ex-PSJ president surviving high-stage cancer
○Eiichi Kimura1,2,3(1. PSJ Honorary member, 2. Professor Emeritus, Hiroshima Univ., 3. Visiting Professor, Shizuoka Univ.)
[IPL]Accelerating tuberculosis drug development
○Stewart T. Cole1(1. Institut Pasteur)
[ISL]Total synthesis of complex terpenoid natural products
○Seth B. Herzon1(1. Dept. Chem., Yale Univ)
[SL01]Recent trends in genome editing research
○Takashi Yamamoto1,2(1. Grad. School of Integrated Sciences for Life, Hiroshima Univ., 2. Hiroshima Univ. Genome Editing Innovation Center)
[SL02]Kampo medicine (Japanese herbal medicine) induced pneumonitis (with thinking about clinical pharmacists)
○Masamitsu Nakajima1(1. Hiroshima International University, Faculty of Pharmaceutical Sciences)
[SL03]Recent initiatives for expedited review and new modalities in PMDA
○Hiroyuki Arai1,2(1. PMDA, 2. Univ. Tokyo Med.)
[SL04]Advances of CNS Drug Innovation in Pharmaceutical Sciences
○Kohji Fukunaga1(1. Tohoku University Graduate School of Pharmaceutical Sciences)
[SL05]From membrane model to liposomal DDS
○Naoto Oku1(1. Faculty of Pharma-Sci, Teikyo Univ)
[SL06]Golden Syrian Hamster as a new model to study mammalian gonad maturation
○Haruhiko Siomi1(1. Keio University School of Medicine)
[SL07]Reasonable Accommodation in Pharmacies - What has been changed by the Act for Eliminating Discrimination Against Persons with Disabilities?
○Mamiko Sakata1(1. Doshisha Univ.)
[SL08]Pharmacists of the future to support healthcare system
○Kazuo Matsubara1,2(1. School of Pharmaceutical Sciences, Wakayama Medical University, 2. Department of Pharmacy, Wakayama Medical University Hospital)
[SL09]Epidemiological analysis of novel coronavirus (COVID-19) using mathematical models
○Hiroshi Nishiura1(1. Kyoto University, Graduate School of Medicine)
[SL10]Utilization of Large-Scale Medical Data for R&D – Next-Generation Medical Information Infrastructure Act-
○Keita Komatsu1(1. Cabinet Secretariat, Office of Healthcare Policy)
[SL11]DNA-Carrying Nanoparticles for Diagnostics
○Mizuo Maeda1(1. RIKEN)
[SL12]Synthesis and application of immunomodulating biomolecular conjugates for immunotherapies
○Koichi Fukase1,2(1. Graduate School of Science, Osaka University, 2. Institute for Radiation Sciences, Osaka University)
[AL01]Advanced molecular transformation based on an innovative catalytic system
○Yoshiji Takemoto1(1. Kyoto Univ. Grad. Sch. Pharm. Sci.)
[AL02]Elucidation of complex dynamic intermolecular interactions in membranes
○Katsumi Matsuzaki1(1. Grad. Sch. Pharm. Sci. Kyoto Univ.)
[AL03]Clinical pharmacology research for optimal drug therapy and its application to drug development
○Yusuke Tanigawara1(1. Keio Univ Sch Med)
[AL04]New Methodologies for Synthesis of Bioactive Molecules and Analysis of Their Functions
○Mikiko Sodeoka1(1. RIKEN)
[AL05]Chrono-pharmaceutical study based on the molecular mechanism of circadian rhythms in pathological condition and drug efficacy
○Satoru Koyanagi1(1. Fac. Pharm. Sci., Kyushu Univ.)
[AL06]Functional study of TNFR-II signal and drug discovery using a protein engineering method
○Shin-ichi Tsunoda1(1. Fac. Pharm. Sci., Kobe Gakuin Univ.)
[AL07]Biosynthetic studies on marine natural products
○Toshiyuki Wakimoto1(1. Faculty of Pharm. Sci., Hokkaido Univ.)
[AL08]Development of lipid nanoparticles for efficient and safe delivery of macromolecules
○Yusuke Sato1(1. Fac. Pharm. Sci., Hokkaido Univ.)
[AL09]Development of tyrosine chemical modifications and elucidation of biological function
○Shinichi Sato1(1. Tohoku Univ. FRIS)
[AL10]Development of next-generation cell-based therapy by regulating cell-cell interactions
○Kosuke Kusamori1(1. Fac. Pharm. Sci., Tokyo Univ. Sci.)
[AL11]Elucidation of the pathological molecular mechanisms underlying trans-fatty acid-related diseases
○Yusuke Hirata1(1. Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)
[AL12]Development of Novel Reaction Property of Metal-Carbene Species and Synthetic Applications
○Shingo Harada1(1. Grad. Sch. of Pharm. Sci., Chiba Univ.)
[AL13]Total synthesis and functional analysis of complex peptidic natural products and their artificial analogues
○Hiroaki Itoh1(1. Grad. Sch. Pharm. Sci., The Univ. of Tokyo)
[AL14]Development of Catalytic Reactions toward Underexplored Chemical Space
○Hidetoshi Noda1(1. BIKAKEN)
[AL15]Peptide tool-driven functional elucidation of biomolecules related to endocrine and metabolism
○Kentaro Takayama1(1. Kyoto Pharm. Univ.)
[AL16]Discovery research of Perampanel as AMPA-type glutamate receptor antagonist
○Satoshi Nagato1, Koshi Ueno1, Masataka Ueno2, Osamu Takenaka3, Takahisa Hanada4(1. Intellectual Property Department, Eisai Co., Ltd., 2. Dementia total inclusive ecosystem, Eisai Co., Ltd. (former), 3. Pharmacology Science Department, Medicine Development Center, Eisai Co., Ltd., 4. Strategy Planning & Operations, Medicine Development Center, Eisai Co., Ltd.)
[AL17]Exploring the risk factors of dry skin in humans and it's pharmacotherapy
○Kazuya Ooi1(1. Faculty of Pharm. Sci, Suzuka Univ. of Med. Sci.)
[IS01-1]Pharmacy's response to the pandemic
○Dominique Jordan1(1. lnternational Pharmaceutical Federation, FIP)
[IS01-2]Challenge for COVID-19 in regulatory authorities
○Junko Sato1(1. Pharmaceuticals and Medical Devices Agency)
[IS01-3]Activities and roles of Japanese pharmacists during the spread of COVID-19 infection
○Nobuo Yamamoto1(1. Japan Pharmaceutical Association)
[IS01-4]Experience of urgent drug development in a pandemic environment, delivering the first approved anti-COVID-19 treatment - Trials, Access, and Manufacturing -
○Luc Hermans1(1. Gilead Sciences Inc)
[IS02-1]Development of anti-RNA virus nucleosides
○Lak Shin Jeong1(1. Dept. of Med. Chem., College of Pharm., Seoul Natl. Univ.)
[IS02-2]Drug discovery research against COVID-19 under interdisciplinary collaboration
○Koichi Watashi1(1. Dep. Virol. II, Nat. Inst. Infect. Dis.)
[IS02-3]Discovery, structure-activity relationships and optimization studies of 3C protease inhibitors of coxsackievirus B3
Bo-Kyoung Kim1, Won-Gil Lee1, Eun-Seok Jeon2, ○Yong-Chul Kim1(1. Sch. Life Sci., Gwangju Inst. of Sci. & Tech. (GIST), 2. Div. Cardiol., Samsung Med. Cent., Sungkyunkwan Univ. Sch. Med.)
[IS02-4]Identification and development of novel compounds inhibitory to SARS-CoV-2 replication
○Masanori Baba1, Mika Okamoto1, Shin Aoki2, Yoshiki Yagi3, Masaaki Toyama1, Tomohiro Tanaka2, Takuro Niwa3(1. Joint Res. Ctr. Hum. Retrovirus Infect., Kagoshima Univ., 2. Faculty Pharm. Sci., Tokyo Univ. Sci., 3. Nobelpharma)
[OS01-1]About the future policy for the gender equality
○Yoko Furuse1(1. Gender Equality Bureau Cabinet Office)
[OS01-2]Diversity & inclusion initiatives in pharmaceutical industry -transition of industrial network -
○Maiko Tsukiji1(1. Daiichi-Sankyo)
[OS01-3]Gender equality action in science council of Japan: discussion of gender diversity in life science field
○Midori Hirai1(1. Jpn Red Cross Hyogo Blood Center)
[S01-1]Development of immuno-regulatory methods using designer exosomes
○Rikinari Hanayama1(1. WPI-NanoLSI, Kanazawa Univ.)
[S01-2]Development of exosome-based immunotherapy
○Yuki Takahashi1(1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
[S01-3]Diversity analysis of exosomes and application to DDS
○Kazunari Akiyoshi1(1. Sch. Eng., Kyoto Univ.)
[S01-4]Development of functionalized exosomes using peptides modified lipid
○Shigeru Kawakami1, Yuri Sugimoto1(1. Grad. Sch. Biomed. Sci., Nagasaki Univ.)
[S02-1]Engineered biosynthesis of microbial medicinally active compounds
○Takayoshi Awakawa1(1. Univ. of Tokyo, Grad. Sch. of Pharm. Sci.)
[S02-2]A strategy for “point mutation” of natural products: modular expeditious synthesis of middle-sized molecules and lead generation
○Hiroki Oguri1(1. Graduate School of Science, The University of Tokyo)
2,821 results ( 1 - 50 )
- 1
- ...